Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Inv. presentation
Quarterly results
|
|
Furiex Pharmaceuticals, Inc. (FURX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/28/2014 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger, by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc",
"Form of Contingent Value Rights Agreement by and between Forest Laboratories, Inc., and the Rights Agent",
"Stockholder Voting Agreement, by and between Forest Laboratories, Inc. and Fredric N. Eshelman, Pharm.D. and certain affiliates of Dr. Eshelman",
"Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest - Acquisition Adds Global Rights to Eluxadoline - New Drug Application Expected to be Filed in 2014 - Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest's GI Treatments Acquired in Acquisition of Aptalis Forest to Partner with Royalty Pharma by Divesting Furiex's Royalty" |
|
|
|